Newsroom
Sorted by: Latest
-
Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Space Economy UCITS ETF 07.08.2026 FSPC.LN IE000ANMCD25 50,002.00 USD 1,111,871.18 22.237 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - March 07.08.2026 MMAR.LN IE0002PPCMH6 50,002.00 USD 1,340,920.53 26.817 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Nuclear Power UCITS ETF 07.08.2026 RCTR.LN IE000J5PESP7 2,550,002.00 USD 46,629,432.33 18.286 ...
-
Cadeler Strengthens Future Installation Capacity With Firm Orders for Two New T-class Vessels
COPENHAGEN, Denmark--(BUSINESS WIRE)--Cadeler today announces that it has signed firm contracts with COSCO Shipping Offshore shipyard in Qidong, China, for the construction of two new T-class offshore wind installation vessels, scheduled for delivery in 2030 and 2031. Earlier this year, Cadeler secured the equity financing for this investment as part of its long-term strategy to become the preferred offshore wind installation partner and to support the continued growth of the offshore wind indu...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Rising Dividend Achievers UCITS ETF 07.08.2026 EDVY.LN IE000CPG9HG3 50,002.00 EUR 1,163,087.15 23.261 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 07.08.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,420,889.20 28.417 ...
-
PaysafeWallet Is Now Live in Poland: Your Money, Your Way
LONDON--(BUSINESS WIRE)--Paysafe (NYSE: PSFE), PaysafeWallet has arrived in Poland and it’s built for a new generation. Polish consumers can now access a digital wallet giving them their own personal debit card, on their phone, built for the way they live, spend and have fun today. Poland has strong adoption of PaysafeCard, and this builds on that foundation. PaysafeWallet extends what customers already trust into a broader, more complete wallet experience. With PaysafeWallet, everything is in...
-
Insyde® Software Qualifies Firmware for Arm® AGI CPU Platforms
TAIPEI, Taiwan--(BUSINESS WIRE)--OCP APAC SUMMIT -- Insyde® Software, a worldwide provider of UEFI and OpenBMC firmware for AI Infrastructure, today announced that InsydeH2O® UEFI firmware is qualified on Arm® AGI CPU reference platforms, giving platform developers a proven, production-ready firmware foundation for next-generation agentic AI data center deployments. In addition, Insyde has readied its production verified Supervyse® OPF OpenBMC firmware for Arm AGI CPU-based AI server racks. Thi...
-
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding So...